FMP
Vaxcyte, Inc.
PCVX
NASDAQ
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
75.23 USD
0.86 (1.14%)
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
34.03M
72.83M
46.83M
78.59M
47.07M
57.9M
71.22M
87.61M
107.76M
132.56M
-
114
-35.71
67.84
-40.11
23.01
23.01
23.01
23.01
88.13M
-128.95M
-153.09M
-102.83M
-194.5M
-34.74M
-42.73M
-52.57M
-64.66M
-79.53M
258.95
-177.05
-326.92
-130.84
-413.2
-60
-60
-60
-60
-9.1M
-1.6M
-2.84M
-34.48M
-12.84M
-12.29M
-15.12M
-18.59M
-22.87M
-28.13M
-26.73
-2.19
-6.06
-43.87
-27.27
-21.22
-21.22
-21.22
-21.22
79.03M
-130.54M
-155.92M
-137.31M
-207.34M
-47.03M
-57.85M
-71.16M
-87.53M
-107.67M
34.49
75.04M
4.11
4.11
87.76M
2.59B
2.68B
3.28
96.72
14.27
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
34.03M
72.83M
46.83M
78.59M
47.07M
57.9M
71.22M
87.61M
107.76M
132.56M
88.13M
-128.95M
-153.09M
-102.83M
-194.5M
-34.74M
-42.73M
-52.57M
-64.66M
-79.53M
-9.1M
-1.6M
-2.84M
-34.48M
-12.84M
-12.29M
-15.12M
-18.59M
-22.87M
-28.13M
79.03M
-130.54M
-155.92M
-137.31M
-207.34M
-47.03M
-57.85M
-71.16M
-87.53M
-107.67M
14.27
14.27
14.27
14.27
14.27
-41.16M
-44.3M
-47.68M
-51.33M
-55.25M
-239.72M
14.27
-109.82M
-894.7M
-459.12M
-698.84M
-32.49M
-666.35M
75.04M
-8.88
-8.88 4.884%